Effectiveness and safety of degarelix compared to... - Gonadorelin Study

Key Findings

Higher overall adverse‑event rate with degarelix (≈60% vs 48% for agonists), driven mainly by injection‑site reactions.

Significantly lower cardiovascular (6.1% vs 7.8%) and musculoskeletal (12.7% vs 15.2%) adverse events.

Much quicker and more complete testosterone suppression (96.5% castration by day 3, 96.1% suppression at 12 months).

Practical Outcomes

For anyone experimenting with hormone control, degarelix offers rapid and reliable testosterone knock‑down and may be safer for heart and joint health, but expect frequent injection‑site irritation. Weigh the speed and cardiovascular benefit against the higher local reaction rate when choosing a protocol.

Summary

Degarelix, a GnRH‑antagonist, causes faster and more lasting testosterone drop than traditional GnRH‑agonists, cuts down heart‑related and muscle‑joint side effects, but it gives many more injection‑site reactions and overall mild side effects.

Abstract

This meta-analysis compared the efficacy and safety of degarelix and GnRH agonists in prostate cancer treatment. A comprehensive literature search was carried out using PubMed, Web of Science, Cochrane Library, and Scopus. RevMan 5.3 software was applied to conduct the meta-analysis. Degarelix resulted in a higher frequency of adverse events compared to GnRH agonists (59.7% vs 48.4%; RR: 1.07, 95%CI: 1.02-1.13, p < 0.001). However, these events did not translate into a higher rate of severe complications (10.8% vs 11.8%; RR: 0.89, 95%CI: 0.66-1.19, p = 0.43), treatment discontinuation (5.5% vs 5.5%; RR:1.00, 95%CI: 0.67-1.50, p = 0.99) or death (2.5% vs 3.9%; RR: 0.64, 95%CI: 0.34-1.19, p = 0.16). Degarelix triggered higher incidence of injection site reaction (45.3%vs 4.4%; RR: 19.17, 95%CI: 5.51-66.74, p < 0.00001), but contributed to lower rates of cardiovascular events (6.1% vs 7.8%; RR: 0.7, 95%CI: 0.51-0.96, p = 0.03), musculoskeletal events (12.7% vs 15.2%; RR: 0.79, 95%CI: 0.65-0.95, p = 0.01) and urinary adverse effects (AEs) (6.4% vs 14.1%; RR: 0.46, 95%CI: 0.33-0.63, p < 0.00001). Degarelix provided better relief of IPSS (MD -1.85, 95%CI: -2.97- -0.72, P = 0.001) and was linked to reduced prostate volume (MD -1.4, 95%CI: -4.83-2.02, P = 0.42). There was no significant difference in PSA progression at 12 months (13.3% vs 14%; RR: 0.88, 95%CI: 0.73-1.06, p = 0.17). However, degarelix achieved significantly higher castration rates at day 3 (96.5% vs 0%; RR: 356.05, 95%CI: 87.57-1447.68, p < 0.00001) and more sustained testosterone suppression at 12 months (96.1% vs 74.3%; RR: 1.3, 95%CI: 1.02-1.66, p = 0.03). While degarelix is associated with higher overall AE rates, it provides significant benefits in terms of cardiovascular and musculoskeletal safety, rapid testosterone suppression, and lower urinary AEs.

Study Information

Provider

pubmed

Year

2025

Date

2025-11-11T00:00:00.000Z

DOI

10.1080/13685538.2025.2581656

References